Global Cardiology Academy

When GDMT Isn’t Enough: Understanding Residual Risk in Patients with HFrEF
When GDMT Isn’t Enough: Understanding Residual Risk in Patients with HFrEF
MinuteCE®
When GDMT Isn’t Enough: Understanding Residual Risk in Patients with HFrEF
0.75 program credits
- Javed Butler, MD
0.75 program credits
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
MinuteCE®
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
0.75 program credits
0.75 program credits
MinuteCE®
The Ambulatory HFrEF Blind Spot: Proactively Reducing CV Mortality Risk Despite Optimized GDMT
0.75 credits 5 episodes
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
- Javed Butler, MD
- Prof. Dr. Johann Bauersachs
0.75 credits 5 episodes
Safety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice
Safety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice
MinuteCE®
Safety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice
0.75 program credits
- Prof. Dr. Johann Bauersachs
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
0.75 program credits
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
On the Frontlines of ATTR-CM
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
- Ryan Quigley
- Ahmad Masri, MD, MS
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
CME/CE
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
0.25 credits
- Stephen J. Greene, MD, FACC, FHFSA
- Gianluigi Savarese, MD
0.25 credits
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Heart Matters
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
- Ahmad Masri, MD, MS
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Heart Matters
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
- Kevin Alexander

Programs

GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
CME/CE
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
0.25 credits
- Prof. Dr. Johann Bauersachs
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
0.25 credits
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Global Neurology Academy
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
- Mike Sharma, MD, MSc, FRCPC
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Global Neurology Academy
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
- Ashkan Shoamanesh, MD
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
On the Frontlines of ATTR-CM
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
- Ryan Quigley
- Kevin Alexander, MD
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
CME/CE
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
0.50 credits
- Richard E. Pratley, MD
- David Cherney, MD, PhD
- prof. Hiddo Heerspink
0.50 credits
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
On the Frontlines of ATTR-CM
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
- Ryan Quigley
- Quan Bui, MD
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
AudioAbstracts
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
- Hallie Blevins, PhD
Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
CME/CE
Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
0.25 credits
- Erin Bohula, MD, DPhil
- Lawrence Leiter
0.25 credits

Clinical Practice

Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Heart Matters
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
- Quan Bui, MD
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Heart Matters
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Closing Gaps in ASCVD Prevention: Lipid Management Insights from AHA 2025
Closing Gaps in ASCVD Prevention: Lipid Management Insights from AHA 2025
Heart Matters
Closing Gaps in ASCVD Prevention: Lipid Management Insights from AHA 2025
- Laurence Sperling, MD
- Eugenia Gianos, MD
Managing Concomitant Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Evolving Care Strategies
Managing Concomitant Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Evolving Care Strategies
AudioAbstracts
Managing Concomitant Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Evolving Care Strategies
- Marlene Mimi Maeusli, PhD.
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
Cardiology
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
- Pam R. Taub, MD, FACC, FASPC
Highlights of the Latest Hypertension Guidelines
Highlights of the Latest Hypertension Guidelines
Cardiology
Highlights of the Latest Hypertension Guidelines
- Clyde W. Yancy, MD
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart Matters
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
- Jun-ichi Abe
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Heart Matters
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control

CME

The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
CME/CE
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
0.50 credits
- prof. Hiddo Heerspink
- Peter Rossing, MD, DMSc
- Paola Fioretto, MD
0.50 credits
MinuteCE®
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
1.00 credit 9 episodes
- James Burton, DM, FRCP
- Leonie Kraft, MD
- Lucio Manenti, MD, PhD
- Emilio Sanchez, MD, PhD
1.00 credit 9 episodes
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
CME/CE
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
0.25 credits
- John McMurray, MD
- Scott Solomon, MD
0.25 credits
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Cardiology
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
- Daniel Judge, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Cardiology
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
- Kevin Alexander, MD
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
CME/CE
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
0.50 credits
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Amy Mottl, MD, MPH
- Muthiah Vaduganathan, MD, MPH
0.50 credits
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
Cardiology
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
- Ahmad Masri, MD, MS
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
CME/CE
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
0.25 credits
- Riccardo Maria Inciardi, MD, PhD
0.25 credits